Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company
|
|
Novartis CEO Vasant Narasimhan discusses how he transformed a 250-year-old conglomerate into a focused medicines company, unlocking $180 billion in value whilst advancing breakthrough therapies in cell, gene, and RNA medicines.
|
|
●
|
Spun off three public companies and refocused Novartis on four disease areas and three platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies.
|
|
●
|
Cell therapies now show extraordinary potential in autoimmune disease, with patients experiencing near-complete disease reversal and functional cures alongside improved manufacturing economics.
|
|
●
|
AI is maturing as an enabling technology across R&D, with potential to shorten drug development timelines by two to four years and improve clinical trial success rates.
|
|
|
"The fact that we still treat disease as late as we do, when we know that if you treat earlier, you're going to win. We have not solved this problem at scale." - Vasant Narasimhan
|
|